Fever with rash in COVID-19: viral exanthema or secondary lesions?

M. Goldust,A. Abdelmaksoud,Z. Shuang,C. Xiang,A. A. Navarini
DOI: https://doi.org/10.1111/jdv.16639
2020-01-01
Journal of the European Academy of Dermatology and Venereology
Abstract:<title xmlns="https://jats.nlm.nih.gov/ns/archiving/1.2/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">Abstract</title> <p xmlns="https://jats.nlm.nih.gov/ns/archiving/1.2/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">COVID‐19 originated in Wuhan, China and has developed into a pandemic since late 2019. The virus possesses powerful pathogenicity as well as transmissibility. Many open questions remain, including the description of potential involvement of other organs than the respiratory tract. Most patients have mild influenza‐like symptoms. A minority, especially patients with chronic lung disease, develops lethal disease including severe pneumonia, pulmonary edema, rapidly developing acute respiratory distress syndrome (ARDS), multiple organ failure and septic shock.</p>
What problem does this paper attempt to address?